Search Results - "Param, Nesteene J"

Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor by Vitiello, Gerardo A, Medina, Benjamin D, Zeng, Shan, Bowler, Timothy G, Zhang, Jennifer Q, Loo, Jennifer K, Param, Nesteene J, Liu, Mengyuan, Moral, Alec J, Zhao, Julia N, Rossi, Ferdinand, Antonescu, Cristina R, Balachandran, Vinod P, Cross, Justin R, DeMatteo, Ronald P

“…Imatinib dramatically reduces gastrointestinal stromal tumor (GIST) F-FDG uptake, providing an early indicator of treatment response. Despite decreased glucose…”
Get full text

Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor by Vitiello, Gerardo A, Bowler, Timothy G, Liu, Mengyuan, Medina, Benjamin D, Zhang, Jennifer Q, Param, Nesteene J, Loo, Jennifer K, Goldfeder, Rachel L, Chibon, Frederic, Rossi, Ferdinand, Zeng, Shan, DeMatteo, Ronald P

“…Gastrointestinal stromal tumor (GIST) is the most common human sarcoma, frequently characterized by an oncogenic mutation in the KIT or platelet-derived growth…”
Get full text

Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in PDGFRA D842V-Mutant Gastrointestinal Stromal Tumor by Rossi, Ferdinand, Liu, Mengyuan, Tieniber, Andrew, Etherington, Mark S, Hanna, Andrew, Vitiello, Gerardo A, Param, Nesteene J, Do, Kevin, Wang, Laura, Antonescu, Cristina R, Zeng, Shan, Zhang, Jennifer Q, DeMatteo, Ronald P

“…To create an in vivo model of PDGFRA D842V-mutant gastrointestinal stromal tumor (GIST) and identify the mechanism of tumor persistence following avapritinib…”
Get full text

Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity by Medina, Benjamin D, Liu, Mengyuan, Vitiello, Gerardo A, Seifert, Adrian M, Zeng, Shan, Bowler, Timothy, Zhang, Jennifer Q, Cavnar, Michael J, Loo, Jennifer K, Param, Nesteene J, Maltbaek, Joanna H, Rossi, Ferdinand, Balachandran, Vinod, DeMatteo, Ronald P

“…Gastrointestinal stromal tumor (GIST) is driven by an activating mutation in the proto-oncogene. Using a mouse model of GIST and human specimens, we show that…”
Get full text

The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor by Zhang, Jennifer Q., Bosbach, Benedikt, Loo, Jennifer K., Vitiello, Gerardo A., Zeng, Shan, Seifert, Adrian M., Medina, Benjamin D., Param, Nesteene J., Maltbaek, Joanna H., Rossi, Ferdinand, Antonescu, Cristina R., Besmer, Peter, DeMatteo, Ronald P.

“…Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and arises in the gastrointestinal tract. Most GISTs are caused by activating mutations…”
Get full text

Adeno-associated virus-mediated trastuzumab delivery to the central nervous system for human epidermal growth factor receptor 2+ brain metastasis by Werner, Marcela S., Aras, Shweta, Morgan, Ashleigh R., Roamer, Jillian, Param, Nesteene J., Olagbegi, Kanyin, Lamontagne, R. Jason, Greig, Jenny A., Wilson, James M.

“…Trastuzumab improves overall survival for HER2+ breast cancer, but its short half-life in the cerebrospinal fluid (~2–4 days) and delivery limitations restrict…”
Get full text

Macrophages and CD8 + T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors by Zhang, Jennifer Q, Zeng, Shan, Vitiello, Gerardo A, Seifert, Adrian M, Medina, Benjamin D, Beckman, Michael J, Loo, Jennifer K, Santamaria-Barria, Juan, Maltbaek, Joanna H, Param, Nesteene J, Moral, John A, Zhao, Julia N, Balachandran, Vinod, Rossi, Ferdinand, Antonescu, Cristina R, DeMatteo, Ronald P

“…Tyrosine kinase inhibition of gastrointestinal stromal tumors (GIST) is effective but typically culminates in resistance and is rarely curative. Immunotherapy…”
Get more information

Oncogenic KIT Modulates Type I IFN-Mediated Antitumor Immunity in GIST by Liu, Mengyuan, Etherington, Mark S, Hanna, Andrew, Medina, Benjamin D, Vitiello, Gerardo A, Bowler, Timothy G, Param, Nesteene J, Levin, Lillian, Rossi, Ferdinand, DeMatteo, Ronald P

“…Type I IFNs are implicated in tumor immunogenicity and response to systemic therapy, but their interaction with oncogene signaling is not well understood…”
Get more information

ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor by Zeng, Shan, Seifert, Adrian M, Zhang, Jennifer Q, Kim, Teresa S, Bowler, Timothy G, Cavnar, Michael J, Medina, Benjamin D, Vitiello, Gerardo A, Rossi, Ferdinand, Loo, Jennifer K, Param, Nesteene J, DeMatteo, Ronald P

“…Gastrointestinal stromal tumor (GIST) is the most common sarcoma, often resulting from a or platelet-derived growth factor receptor alpha ( ) mutation. The…”
Get full text

Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor by Rossi, Ferdinand, Liu, Mengyuan, Tieniber, Andrew, Etherington, Mark S., Hanna, Andrew, Vitiello, Gerardo A., Param, Nesteene J., Do, Kevin, Wang, Laura, Antonescu, Cristina R., Zeng, Shan, Zhang, Jennifer Q., DeMatteo, Ronald P.

Get full text

Abstract LB201: Optimizing adeno-associated viral vector-mediated delivery of trastuzumab to the central nervous system for the treatment of Her2 positive brain metastasis by Werner, Marcela Salazar, Aras, Shweta, Morgan, Ashleigh, Param, Nesteene J., Greig, Jenny, Wilson, James M.

“…Abstract Breast cancer is the most common cause of brain metastases in women, affecting 15-30% of all patients. Despite the success of systemic Her2-targeted…”
Get full text